Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
Shuyu HuangSander M J van DuijnhovenAlice J A M SijtsAndrea van ElsasPublished in: Journal of cancer research and clinical oncology (2020)
Dual TAAs targeting BsAbs represent a valuable class of biologics and early stage clinical studies have demonstrated promising anti-tumor efficacy in both hematologic malignancies and solid tumors.